Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease (NCT05297812)
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease - Alpha-1 Biomarker Research Consortium (A1BC)
🩺 Plain-English Summary (8th-Grade Level)
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- University of Alabama at Birmingham — Birmingham, Alabama
- University of California - Los Angeles — Los Angeles, California
- National Jewish Health — Denver, Colorado
- University of Chicago — Chicago, Illinois
- Boston University — Boston, Massachusetts
- Columbia University — New York, New York
- University of North Carolina — Chapel Hill, North Carolina
- Medical University of South Carolina — Charleston, South Carolina
- University of Utah — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alpha 1-Antitrypsin Deficiency
- Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants — San Diego, California
- Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema — Birmingham, Alabama
- A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) — Birmingham, Alabama
- Alpha-1 Research Registry — Coral Gables, Florida
- Gene Therapy for Alpha 1- Antitrypsin Deficiency — New York, New York
Explore by condition: All Alpha 1-Antitrypsin Deficiency clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.